Guizhu Liu1, Qian Liu2, Yujun Shen2, Deping Kong2, Yanjun Gong1, Bo Tao1, Guilin Chen2, Shumin Guo1, Juanjuan Li3, Shengkai Zuo1, Yu Yu1, Huiyong Yin1, Li Zhang4, Bin Zhou5, Colin D Funk6, Jian Zhang2, Ying Yu2. 1. Key Laboratory of Food Safety Research, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. 2. Department of Pharmacology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070, China. 3. Department of Gastroenterology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. 4. Department of Cardiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, 310003, China. 5. The State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, 200031, China. 6. Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, K7L3N6, Canada.
Abstract
BACKGROUND AND PURPOSE: An appropriate inflammatory response is necessary for cardiac healing after acute myocardial infarction (MI). Resolvin E1 (RvE1) is an anti-inflammatory and pro-resolution lipid mediator derived from eicosapentaenoic acid. Here we have investigated the effects of RvE1 on the recovery of cardiac function after MI in mice. EXPERIMENTAL APPROACH: Acute MI was induced by surgical ligation of the left anterior descending artery in male C57BL/6 mice. RvE1 (5 ng·g-1 ·day-1 ; i.p.) was given to mice at different times following MI. Cardiac function was monitored by transthoracic echocardiography at days 3, 7 and 14 after MI. Effects of RvE1 on the migration of subpopulations of monocytes/macrophages (Mos/Mps, Ly6Chi and Ly6Clow ) were examined by flow cytometry and transwell assay. KEY RESULTS: RvE1 administration from days 1 to 7 post-MI improved cardiac function, whereas treatment from days 7 to 14 markedly inhibited recovery of cardiac function. Early treatment with RvE1 post-MI suppressed the infiltration of dominant Ly6Chi Mos/Mps and secretion of pro-inflammatory cytokines in injured hearts, which protected cardiomyocytes against apoptosis in the peri-infarct zones. Contrastingly, treatment with RvE1 1 week after MI decreased infiltration of Ly6Clow Mos/Mps and expression of pro-angiogenic factors in cardiac tissue, consequently reducing neovascularization in the peri-infarct zones. Additionally, RvE1 inhibited Mp migration by activating ChemR23 receptors. CONCLUSION AND IMPLICATIONS: Treatment with RvE1 during the initial 7 days after MI facilitated cardiac healing by suppressing pro-inflammatory cytokine secretion, indicating that RvE1 may serve as an early therapeutic agent for acute MI. LINKED ARTICLES: This article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc.
BACKGROUND AND PURPOSE: An appropriate inflammatory response is necessary for cardiac healing after acute myocardial infarction (MI). Resolvin E1 (RvE1) is an anti-inflammatory and pro-resolution lipid mediator derived from eicosapentaenoic acid. Here we have investigated the effects of RvE1 on the recovery of cardiac function after MI in mice. EXPERIMENTAL APPROACH: Acute MI was induced by surgical ligation of the left anterior descending artery in male C57BL/6 mice. RvE1 (5 ng·g-1 ·day-1 ; i.p.) was given to mice at different times following MI. Cardiac function was monitored by transthoracic echocardiography at days 3, 7 and 14 after MI. Effects of RvE1 on the migration of subpopulations of monocytes/macrophages (Mos/Mps, Ly6Chi and Ly6Clow ) were examined by flow cytometry and transwell assay. KEY RESULTS: RvE1 administration from days 1 to 7 post-MI improved cardiac function, whereas treatment from days 7 to 14 markedly inhibited recovery of cardiac function. Early treatment with RvE1 post-MI suppressed the infiltration of dominant Ly6Chi Mos/Mps and secretion of pro-inflammatory cytokines in injured hearts, which protected cardiomyocytes against apoptosis in the peri-infarct zones. Contrastingly, treatment with RvE1 1 week after MI decreased infiltration of Ly6Clow Mos/Mps and expression of pro-angiogenic factors in cardiac tissue, consequently reducing neovascularization in the peri-infarct zones. Additionally, RvE1 inhibited Mp migration by activating ChemR23 receptors. CONCLUSION AND IMPLICATIONS: Treatment with RvE1 during the initial 7 days after MI facilitated cardiac healing by suppressing pro-inflammatory cytokine secretion, indicating that RvE1 may serve as an early therapeutic agent for acute MI. LINKED ARTICLES: This article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc.
Authors: Oliver Dewald; Pawel Zymek; Kim Winkelmann; Anna Koerting; Guofeng Ren; Tareq Abou-Khamis; Lloyd H Michael; Barrett J Rollins; Mark L Entman; Nikolaos G Frangogiannis Journal: Circ Res Date: 2005-03-17 Impact factor: 17.367
Authors: Christopher Southan; Joanna L Sharman; Helen E Benson; Elena Faccenda; Adam J Pawson; Stephen P H Alexander; O Peter Buneman; Anthony P Davenport; John C McGrath; John A Peters; Michael Spedding; William A Catterall; Doriano Fabbro; Jamie A Davies Journal: Nucleic Acids Res Date: 2015-10-12 Impact factor: 16.971
Authors: Stephen Ph Alexander; Doriano Fabbro; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Petronela Ancuta; Ravi Rao; Ashlee Moses; Andrew Mehle; Sunil K Shaw; F William Luscinskas; Dana Gabuzda Journal: J Exp Med Date: 2003-06-16 Impact factor: 14.307
Authors: Timothy D O'Connell; Katherine A Murphy; Naixin Zhang; Sara J Puccini; Chastity L Healy; Brian A Harsch; Michael J Zhang; Gregory C Shearer Journal: Physiology (Bethesda) Date: 2022-08-09
Authors: Hylde Zirpoli; Chuchun L Chang; Yvon A Carpentier; Adina T Michael-Titus; Vadim S Ten; Richard J Deckelbaum Journal: Annu Rev Nutr Date: 2020-09-23 Impact factor: 11.848
Authors: Svenja Hinrichs; Katharina Scherschel; Saskia Krüger; Johannes Tobias Neumann; Michael Schwarzl; Isabell Yan; Svenja Warnke; Francisco M Ojeda; Tanja Zeller; Mahir Karakas; Till Keller; Christian Meyer; Stefan Blankenberg; Dirk Westermann; Diana Lindner Journal: Proc Natl Acad Sci U S A Date: 2018-08-30 Impact factor: 11.205
Authors: Katherine A Murphy; Brian A Harsch; Chastity L Healy; Sonal S Joshi; Shue Huang; Rachel E Walker; Brandon M Wagner; Katherine M Ernste; Wei Huang; Robert C Block; Casey D Wright; Nathan Tintle; Brian C Jensen; Quinn S Wells; Gregory C Shearer; Timothy D O'Connell Journal: Cardiovasc Res Date: 2022-03-16 Impact factor: 10.787
Authors: Finosh G Thankam; Victoria E D Wilson; Mohamed M Radwan; Aleem Siddique; Devendra K Agrawal Journal: Mol Biol Rep Date: 2022-01-21 Impact factor: 2.316